Beta-blockers and RAAS inhibitors may prevent LVEF dysfunction due to breast cancer drugs: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-01-24 05:30 GMT | Update On 2022-01-24 05:33 GMT

Sweden: A meta-analysis suggests that beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) may help in preserving LVEF in women undergoing breast cancer treatment with trastuzumab and/or anthracyclines. The study appears in the European Heart Journal.

Trastuzumab and anthracyclines are used often for the treatment of breast cancer. However, its use may impair myocardial function and reduce left ventricular ejection fraction (LVEF), potentially causing heart failure. Randomized controlled trials (RCTs) have evaluated the effects of BBs, ACEI/ARBs on trastuzumab- and anthracycline-associated cardiotoxicity.

Considering the above, Christian Lewinter, Heart Centre, Karolinska University Hospital, Karolinska Universitetssjukhuset Solna, Solna, Stockholm, Sweden, and colleagues aimed to assess the effect of BBs and ACEI/ARBs on LVEF in patients treated with either trastuzumab, anthracyclines, or both by conducting a meta-analysis of the RCTs in patients with breast cancer.

The researchers conducted primary and secondary analyses. The primary analysis was on the effect of BBs and ACEI/ARBs on LVEF in patients treated with either trastuzumab or anthracyclines. Secondary analysis was done investigating the effect of BBs or ACEI/ARBs on LVEF in trastuzumab and anthracycline treatments. Meta-analysis was conducted to estimate the mean difference (MD) in LVEF between intervention and placebo groups at follow-up.

The analysis included a total of nine RCTs (n = 1362). All patients were women.

Following were the study's key findings:

The baseline LVEF means varied between 59.5% and 66.0%. ACEI/ARB therapy irrespective of concomitant anthracycline or trastuzumab therapy was not significantly associated with improved LVEF compared to placebo (MD, 1.5).
In contrast, BB therapy preserved LVEF significantly better compared with placebo (MD, 2.4).
Both ACEI/ARBs and BBs were associated with preservation of LVEF compared to placebo in recipients of trastuzumab alone (MD, 2.3), but not anthracycline alone (MD, 1.9).
Whether LVEF was a primary outcome or not did not influence the MD, nor did the imaging modality.

To conclude, both BB and ACEI/ARB therapies were linked to the preservation of LVEF during trastuzumab and anthracycline-containing regimens as compared with placebo, suggesting both to be beneficial.

Reference:

Christian Lewinter, Torsten Holm Nielsen, Lars Robert Edfors, Cecilia Linde, John Martin Bland, M LeWinter, John G F Cleland, Lars Køber, Frieder Braunschweig, Agneta Mansson-Broberg, A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer, European Heart Journal, 2021;, ehab843, https://doi.org/10.1093/eurheartj/ehab843

Article Source : European Heart Journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Beta-blockers and RAAS inhibitors may prevent LVEF dysfunction due to breast cancer drugs: Study

Similar News

Medical Bulletin 26/July/2025

AI System Shows Consistent Accuracy in Echocardiogram Interpretation: JAMA

Want Lower Blood Pressure? This Juice May Help, Study Finds Out

Loneliness and Anxiety Together May Significantly Heighten Atrial Fibrillation Risk: Study Finds

Machine Learning Flags Key Risks for Early Macular Degeneration: Hypertension, Joint Disorders, and Dyslipidemia: Study

Advanced Age Linked to Poorer TEVAR Outcomes Despite Similar Aortic Remodeling, finds study

Beetroot juice lowers blood pressure in older people by changing oral microbiome, suggests study

Low neighborhood walkability is associated with increased risk of cardiovascular disease: Study